Product Description
Tirzepatide is a novel investigational once-weekly dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist that integrates the actions of both incretins into a single molecule, representing a new class of medicines being studied for the treatment of type 2 diabetes. (Sourced from: https://investor.lilly.com/news-releases/news-release-details/tirzepatide-results-published-lancet-show-superior-a1c-and-body)
Mechanisms of Action: GLP-1 Agonist, GIP Agonist
Novel Mechanism: No
Modality: Peptide/Protein
Route of Administration: Subcutaneous
FDA Designation: Fast Track - Obesity|Obesity, Morbid|Overweight *
Approval Status: Approved
Approved Countries: Australia | Austria | Belgium | Croatia | Czech | Estonia | European Medicines Agency | Finland | Germany | Greece | Hungary | Iceland | Ireland | Israel | Italy | Japan | Latvia | Lithuania | Poland | Portugal | Romania | Saudi Arabia | Slovakia | Spain | Sweden | Switzerland | United Arab Emirates | United Kingdom | United States
Approved Indications: None
Known Adverse Events: None
Company: Eli Lilly
Company Location: INDIANAPOLIS IN 46285
Company CEO: David A. Ricks
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, China, Colombia, Czech Republic, Denmark, France, Germany, Greece, Hungary, India, Israel, Italy, Japan, Korea, Malaysia, Mexico, Netherlands, New Zealand, Norway, Poland, Portugal, Puerto Rico, Romania, Russia, Slovakia, South Africa, South Korea, Spain, Sweden, Switzerland, Taiwan, Turkey, Ukraine, United Kingdom, United States, Unknown Location
Active Clinical Trial Count: 69
Recent & Upcoming Milestones
- Clinical Outcomes Reported - Eli Lilly presented P3 Type 2 Diabetes|Cardiovascular results on 2025-07-30 for Tirzepatide
- Clinical Outcomes Reported - Eli Lilly presented P3 Obesity results on 2025-06-20 for Tirzepatide
- Clinical Outcomes Reported - Eli Lilly presented P3 Heart Failure|Obesity results on 2024-08-01 for Tirzepatide
Highest Development Phases
Phase 3: Apnea|Arthritis, Psoriatic|Colitis, Ulcerative|Crohn Disease|Fatty Liver, Alcoholic|Glucose Metabolism Disorders|Heart Failure, Chronic|Heart Failure, Diastolic|Non-alcoholic Fatty Liver Disease|Obesity|Overweight|Psoriasis|Sleep Apnea, Obstructive|Type 1 Diabetes|Type 2 Diabetes|Weight Gain|Weight Loss
Phase 2: Binge-Eating Disorder|Hepatitis, Alcoholic|Kidney Diseases|Kidney Failure, Chronic|Non-alcoholic Steatohepatitis|Obesity, Morbid|Protein Deficiency
Phase 1: Healthy Volunteers|Pediatric Obesity
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| J3R-MC-YDAE | P1 |
Recruiting |
Obesity|Overweight |
2025-12-01 |
88% |
2025-09-16 |
Primary Endpoints |
| A Study of Tirzepatide (LY3298176) in Pediatric Participants With Obesity | P1 |
Active, not recruiting |
Pediatric Obesity |
2007-09-15 |
2025-07-09 |
Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
| LIBERATE | P2 |
Recruiting |
Binge-Eating Disorder|Overweight|Obesity |
2027-12-01 |
12% |
2025-09-23 |
Primary Endpoints|Start Date|Treatments|Trial Status |
| I8F-MC-GPIG | P2 |
Recruiting |
Type 2 Diabetes|Obesity|Kidney Diseases|Overweight |
2026-12-08 |
12% |
2025-05-02 |
Treatments |
| GYMINDA | P2 |
Recruiting |
Overweight|Obesity, Morbid |
2026-10-23 |
12% |
2025-05-31 |
|
| TREASURE-CKD | P2 |
Active, not recruiting |
Overweight|Obesity|Kidney Failure, Chronic|Type 2 Diabetes |
2026-09-01 |
12% |
2025-07-25 |
Primary Endpoints|Treatments|Trial Status |
| J4Z-MC-GIDF | P2 |
Active, not recruiting |
Overweight|Obesity|Protein Deficiency |
2026-04-01 |
12% |
2025-09-27 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
| I8F-MC-GPIT | P2 |
Active, not recruiting |
Obesity|Type 2 Diabetes |
2026-01-01 |
50% |
2025-05-31 |
Primary Endpoints|Treatments|Trial Status |
| SYNERGY-NASH | P2 |
Completed |
Hepatitis, Alcoholic|Non-alcoholic Steatohepatitis|Fatty Liver, Alcoholic |
2023-12-11 |
82% |
2025-01-25 |
Patient Enrollment|Primary Endpoints|Treatments |
| SURPASS-PEDS | P3 |
Completed |
Type 2 Diabetes|Glucose Metabolism Disorders |
2024-07-30 |
75% |
2025-02-28 |
|
| jRCT2031220154 | P3 |
Recruiting |
Apnea|Obesity |
2024-05-31 |
|||
| The SUMMIT Trial | P3 |
Completed |
Heart Failure, Chronic|Obesity|Heart Failure, Diastolic |
2024-07-02 |
18% |
2024-07-23 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Trial Status |
| SURMOUNT-OSA | P3 |
Completed |
Obesity|Sleep Apnea, Obstructive |
2024-03-12 |
74% |
2025-05-01 |
Primary Endpoints |
| SYNERGY-Outcomes | P3 |
Recruiting |
Non-alcoholic Fatty Liver Disease|Fatty Liver, Alcoholic |
2030-08-01 |
2025-11-06 |
Primary Endpoints|Start Date|Trial Status |
|
| COMMIT-CD | P3 |
Recruiting |
Overweight|Obesity|Crohn Disease |
2028-05-01 |
26% |
2025-08-27 |
Primary Endpoints|Treatments |
| COMMIT-UC | P3 |
Recruiting |
Obesity|Colitis, Ulcerative|Overweight |
2028-04-01 |
26% |
2025-08-27 |
Primary Endpoints |
| SURMOUNT-ADOLESCENTS-2 | P3 |
Recruiting |
Obesity|Weight Gain |
2027-10-01 |
41% |
2025-08-27 |
Primary Endpoints|Treatments |
| AID-JUNCT | P3 |
Recruiting |
Type 1 Diabetes |
2026-06-01 |
2025-06-07 |
||
| SURMOUNT-MAINTAIN | P3 |
Active, not recruiting |
Overweight|Weight Loss|Obesity |
2026-05-01 |
85% |
2025-01-08 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
| TOGETHER-PsO | P3 |
Active, not recruiting |
Psoriasis|Obesity |
2025-12-01 |
22% |
2025-08-27 |
Primary Endpoints|Treatments |
| TOGETHER-PsA | P3 |
Active, not recruiting |
Arthritis, Psoriatic|Obesity |
2025-11-01 |
36% |
2025-10-17 |
Primary Completion Date|Primary Endpoints|Treatments |
| Tirzepatide | P2 |
Recruiting |
Obesity|Overweight |
2028-06-01 |
50% |
2024-12-05 |
Primary Endpoints |
| I6T-MC-AMCE | P3 |
Not yet recruiting |
Overweight|Crohn Disease|Obesity |
2028-05-29 |
26% |
||
| I6T-MC-AMCD | P3 |
Not yet recruiting |
Colitis, Ulcerative|Obesity|Overweight |
2028-04-29 |
26% |
||
| jRCT2031220466 | P3 |
Recruiting |
Overweight|Obesity |
2027-11-30 |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
11/10/2025 |
News Article |
Queer Eye's Tan France helps unthread obesity bias as part of Zepbound's (tirzepatide) 'Changing the Thread Collection' |
|
11/07/2025 |
News Article |
Neurogastrx Announces NG101 Phase 2 Clinical Study Demonstrating Significant Reductions in Nausea and Vomiting Induced by GLP-1 Receptor Agonist Semaglutide |
|
11/06/2025 |
News Article |
Lilly and U.S. government agree to expand access to obesity medicines to millions of Americans |
|
11/06/2025 |
News Article |
Omada Health Announces GLP-1 Prescribing Capability to Support Growing Member Population |